Immune triggers preceding neuralgic amyotrophy
Background and purpose Infections and vaccinations have been identified as potential immunological triggers of neuralgic amyotrophy (NA), but the exact type and frequency of the preceding agents is unknown. Methods This was a multicentre, prospective, observational, matched case–control study. NA wa...
Gespeichert in:
Veröffentlicht in: | European journal of neurology 2024-12, Vol.31 (12), p.e16462-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 12 |
container_start_page | e16462 |
container_title | European journal of neurology |
container_volume | 31 |
creator | Sparasci, Davide Schilg‐Hafer, Lenka Schreiner, Bettina Scheidegger, Olivier Peyer, Anne‐Kathrin Lascano, Agustina Maria Vicino, Alex Décard, Bernhard Friedrich Tsouni, Pinelopi Humm, Andrea Monika Pianezzi, Enea Zezza, Giulia Hundsberger, Thomas Dietmann, Anelia Jung, Hans H. Kuntzer, Thierry Wilder‐Smith, Einar Martinetti‐Lucchini, Gladys Petrini, Orlando Fontana, Stefano Gowland, Peter Niederhauser, Christoph Gobbi, Claudio Ripellino, Paolo |
description | Background and purpose
Infections and vaccinations have been identified as potential immunological triggers of neuralgic amyotrophy (NA), but the exact type and frequency of the preceding agents is unknown.
Methods
This was a multicentre, prospective, observational, matched case–control study. NA was diagnosed by neuromuscular experts according to validated clinical criteria and electrodiagnostic studies. Clinical data and biological samples of NA patients were collected within 90 days from disease onset between June 2018 and December 2023. All NA patients were asked about prior infection and vaccination in the month before disease onset. Serological tests for hepatitis E virus, human immunodeficiency virus, severe acute respiratory syndrome coronavirus 2, Epstein–Barr virus, cytomegalovirus, parvovirus B19, varicella‐zoster virus, Borrelia burgdorferi, Mycoplasma pneumoniae and Bartonella henselae were performed in a central laboratory. Each case was matched with a healthy control for age, sex, place of residence and time of blood collection.
Results
Fifty‐seven patients and corresponding controls were included. The mean age was 45 years for both groups. NA onset was preceded by a symptomatic infectious trigger confirmed by microbiological tests in 15/57 (26.3%) patients. Coronavirus disease 2019 vaccination was considered a potential trigger in 7/57 (12.3%) subjects. An acute viral infection was associated with a bilateral involvement of the brachial plexus (p = 0.003, Cramèr's V = 0.43).
Conclusions
Confirmed immune triggers (infection or vaccination) preceded disease onset in 22/57 (38.6%) NA cases. We suggest to test NA patients in the acute phase for intracellular antigens, especially in the case of concomitant bilateral involvement and hepatitis. |
doi_str_mv | 10.1111/ene.16462 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11554871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3112861386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2992-a1926d06f3719a27f2256d23f17141fd66390d2758591d89634bd8104392aa113</originalsourceid><addsrcrecordid>eNp1kc1LwzAchoMobk4P_gNS8KKHbvklbZqcRMb8gKEXPYesTbuOfpm0Sv97MzuHCuaQBPLw8P7yInQOeApuzXSlp8ACRg7QGALGfaAUDt2dhuCHgGGETqzdYIxJRPAxGlFBWRAyPkbTx7LsKu21Js8ybazXGB3rJK8yr9KdUUWWx54q-7o1dbPuT9FRqgqrz3bnBL3eLV7mD_7y-f5xfrv0YyIE8RUIwhLMUhqBUCRKCQlZQmgKEQSQJoxRgRMShTwUkHDBaLBKOOCACqIUAJ2gm8HbdKtSJ7GuWpdFNiYvlellrXL5-6XK1zKr3yVAGAY82hqudgZTv3XatrLMbayLQlW67qykAIQzoJw59PIPuqk7U7n5HEUYJ27njroeqNjU1hqd7tMAltsapKtBftXg2Iuf8ffk9787YDYAH3mh-_9NcvG0GJSf_9ePOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126823128</pqid></control><display><type>article</type><title>Immune triggers preceding neuralgic amyotrophy</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>Wiley Online Library Journals Frontfile Complete</source><source>PubMed Central</source><creator>Sparasci, Davide ; Schilg‐Hafer, Lenka ; Schreiner, Bettina ; Scheidegger, Olivier ; Peyer, Anne‐Kathrin ; Lascano, Agustina Maria ; Vicino, Alex ; Décard, Bernhard Friedrich ; Tsouni, Pinelopi ; Humm, Andrea Monika ; Pianezzi, Enea ; Zezza, Giulia ; Hundsberger, Thomas ; Dietmann, Anelia ; Jung, Hans H. ; Kuntzer, Thierry ; Wilder‐Smith, Einar ; Martinetti‐Lucchini, Gladys ; Petrini, Orlando ; Fontana, Stefano ; Gowland, Peter ; Niederhauser, Christoph ; Gobbi, Claudio ; Ripellino, Paolo</creator><creatorcontrib>Sparasci, Davide ; Schilg‐Hafer, Lenka ; Schreiner, Bettina ; Scheidegger, Olivier ; Peyer, Anne‐Kathrin ; Lascano, Agustina Maria ; Vicino, Alex ; Décard, Bernhard Friedrich ; Tsouni, Pinelopi ; Humm, Andrea Monika ; Pianezzi, Enea ; Zezza, Giulia ; Hundsberger, Thomas ; Dietmann, Anelia ; Jung, Hans H. ; Kuntzer, Thierry ; Wilder‐Smith, Einar ; Martinetti‐Lucchini, Gladys ; Petrini, Orlando ; Fontana, Stefano ; Gowland, Peter ; Niederhauser, Christoph ; Gobbi, Claudio ; Ripellino, Paolo</creatorcontrib><description>Background and purpose
Infections and vaccinations have been identified as potential immunological triggers of neuralgic amyotrophy (NA), but the exact type and frequency of the preceding agents is unknown.
Methods
This was a multicentre, prospective, observational, matched case–control study. NA was diagnosed by neuromuscular experts according to validated clinical criteria and electrodiagnostic studies. Clinical data and biological samples of NA patients were collected within 90 days from disease onset between June 2018 and December 2023. All NA patients were asked about prior infection and vaccination in the month before disease onset. Serological tests for hepatitis E virus, human immunodeficiency virus, severe acute respiratory syndrome coronavirus 2, Epstein–Barr virus, cytomegalovirus, parvovirus B19, varicella‐zoster virus, Borrelia burgdorferi, Mycoplasma pneumoniae and Bartonella henselae were performed in a central laboratory. Each case was matched with a healthy control for age, sex, place of residence and time of blood collection.
Results
Fifty‐seven patients and corresponding controls were included. The mean age was 45 years for both groups. NA onset was preceded by a symptomatic infectious trigger confirmed by microbiological tests in 15/57 (26.3%) patients. Coronavirus disease 2019 vaccination was considered a potential trigger in 7/57 (12.3%) subjects. An acute viral infection was associated with a bilateral involvement of the brachial plexus (p = 0.003, Cramèr's V = 0.43).
Conclusions
Confirmed immune triggers (infection or vaccination) preceded disease onset in 22/57 (38.6%) NA cases. We suggest to test NA patients in the acute phase for intracellular antigens, especially in the case of concomitant bilateral involvement and hepatitis.</description><identifier>ISSN: 1351-5101</identifier><identifier>ISSN: 1468-1331</identifier><identifier>EISSN: 1468-1331</identifier><identifier>DOI: 10.1111/ene.16462</identifier><identifier>PMID: 39364568</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Biological properties ; Biological samples ; Brachial Plexus Neuritis - etiology ; Case-Control Studies ; Coronaviruses ; COVID-19 ; COVID-19 - complications ; COVID-19 - immunology ; COVID-19 Vaccines - immunology ; Cytomegalovirus ; Disease control ; Epstein-Barr virus ; Female ; Hepatitis ; HIV ; Human immunodeficiency virus ; Humans ; immune trigger ; Immunization ; Immunology ; infection ; Infections ; Male ; Middle Aged ; neuralgic amyotrophy ; Neuromuscular system ; Neuropathies ; Original ; Parsonage–Turner syndrome ; Parvoviruses ; Prospective Studies ; Respiratory diseases ; Serological tests ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Vaccination ; Varicella ; Viral diseases ; Viral infections</subject><ispartof>European journal of neurology, 2024-12, Vol.31 (12), p.e16462-n/a</ispartof><rights>2024 The Author(s). published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.</rights><rights>2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2992-a1926d06f3719a27f2256d23f17141fd66390d2758591d89634bd8104392aa113</cites><orcidid>0000-0002-6190-1633 ; 0000-0002-8662-9656 ; 0000-0001-7572-8811 ; 0000-0001-6420-8124 ; 0000-0002-7554-0664 ; 0000-0002-8949-0645</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554871/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554871/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39364568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sparasci, Davide</creatorcontrib><creatorcontrib>Schilg‐Hafer, Lenka</creatorcontrib><creatorcontrib>Schreiner, Bettina</creatorcontrib><creatorcontrib>Scheidegger, Olivier</creatorcontrib><creatorcontrib>Peyer, Anne‐Kathrin</creatorcontrib><creatorcontrib>Lascano, Agustina Maria</creatorcontrib><creatorcontrib>Vicino, Alex</creatorcontrib><creatorcontrib>Décard, Bernhard Friedrich</creatorcontrib><creatorcontrib>Tsouni, Pinelopi</creatorcontrib><creatorcontrib>Humm, Andrea Monika</creatorcontrib><creatorcontrib>Pianezzi, Enea</creatorcontrib><creatorcontrib>Zezza, Giulia</creatorcontrib><creatorcontrib>Hundsberger, Thomas</creatorcontrib><creatorcontrib>Dietmann, Anelia</creatorcontrib><creatorcontrib>Jung, Hans H.</creatorcontrib><creatorcontrib>Kuntzer, Thierry</creatorcontrib><creatorcontrib>Wilder‐Smith, Einar</creatorcontrib><creatorcontrib>Martinetti‐Lucchini, Gladys</creatorcontrib><creatorcontrib>Petrini, Orlando</creatorcontrib><creatorcontrib>Fontana, Stefano</creatorcontrib><creatorcontrib>Gowland, Peter</creatorcontrib><creatorcontrib>Niederhauser, Christoph</creatorcontrib><creatorcontrib>Gobbi, Claudio</creatorcontrib><creatorcontrib>Ripellino, Paolo</creatorcontrib><title>Immune triggers preceding neuralgic amyotrophy</title><title>European journal of neurology</title><addtitle>Eur J Neurol</addtitle><description>Background and purpose
Infections and vaccinations have been identified as potential immunological triggers of neuralgic amyotrophy (NA), but the exact type and frequency of the preceding agents is unknown.
Methods
This was a multicentre, prospective, observational, matched case–control study. NA was diagnosed by neuromuscular experts according to validated clinical criteria and electrodiagnostic studies. Clinical data and biological samples of NA patients were collected within 90 days from disease onset between June 2018 and December 2023. All NA patients were asked about prior infection and vaccination in the month before disease onset. Serological tests for hepatitis E virus, human immunodeficiency virus, severe acute respiratory syndrome coronavirus 2, Epstein–Barr virus, cytomegalovirus, parvovirus B19, varicella‐zoster virus, Borrelia burgdorferi, Mycoplasma pneumoniae and Bartonella henselae were performed in a central laboratory. Each case was matched with a healthy control for age, sex, place of residence and time of blood collection.
Results
Fifty‐seven patients and corresponding controls were included. The mean age was 45 years for both groups. NA onset was preceded by a symptomatic infectious trigger confirmed by microbiological tests in 15/57 (26.3%) patients. Coronavirus disease 2019 vaccination was considered a potential trigger in 7/57 (12.3%) subjects. An acute viral infection was associated with a bilateral involvement of the brachial plexus (p = 0.003, Cramèr's V = 0.43).
Conclusions
Confirmed immune triggers (infection or vaccination) preceded disease onset in 22/57 (38.6%) NA cases. We suggest to test NA patients in the acute phase for intracellular antigens, especially in the case of concomitant bilateral involvement and hepatitis.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological properties</subject><subject>Biological samples</subject><subject>Brachial Plexus Neuritis - etiology</subject><subject>Case-Control Studies</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Cytomegalovirus</subject><subject>Disease control</subject><subject>Epstein-Barr virus</subject><subject>Female</subject><subject>Hepatitis</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>immune trigger</subject><subject>Immunization</subject><subject>Immunology</subject><subject>infection</subject><subject>Infections</subject><subject>Male</subject><subject>Middle Aged</subject><subject>neuralgic amyotrophy</subject><subject>Neuromuscular system</subject><subject>Neuropathies</subject><subject>Original</subject><subject>Parsonage–Turner syndrome</subject><subject>Parvoviruses</subject><subject>Prospective Studies</subject><subject>Respiratory diseases</subject><subject>Serological tests</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccination</subject><subject>Varicella</subject><subject>Viral diseases</subject><subject>Viral infections</subject><issn>1351-5101</issn><issn>1468-1331</issn><issn>1468-1331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1LwzAchoMobk4P_gNS8KKHbvklbZqcRMb8gKEXPYesTbuOfpm0Sv97MzuHCuaQBPLw8P7yInQOeApuzXSlp8ACRg7QGALGfaAUDt2dhuCHgGGETqzdYIxJRPAxGlFBWRAyPkbTx7LsKu21Js8ybazXGB3rJK8yr9KdUUWWx54q-7o1dbPuT9FRqgqrz3bnBL3eLV7mD_7y-f5xfrv0YyIE8RUIwhLMUhqBUCRKCQlZQmgKEQSQJoxRgRMShTwUkHDBaLBKOOCACqIUAJ2gm8HbdKtSJ7GuWpdFNiYvlellrXL5-6XK1zKr3yVAGAY82hqudgZTv3XatrLMbayLQlW67qykAIQzoJw59PIPuqk7U7n5HEUYJ27njroeqNjU1hqd7tMAltsapKtBftXg2Iuf8ffk9787YDYAH3mh-_9NcvG0GJSf_9ePOA</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Sparasci, Davide</creator><creator>Schilg‐Hafer, Lenka</creator><creator>Schreiner, Bettina</creator><creator>Scheidegger, Olivier</creator><creator>Peyer, Anne‐Kathrin</creator><creator>Lascano, Agustina Maria</creator><creator>Vicino, Alex</creator><creator>Décard, Bernhard Friedrich</creator><creator>Tsouni, Pinelopi</creator><creator>Humm, Andrea Monika</creator><creator>Pianezzi, Enea</creator><creator>Zezza, Giulia</creator><creator>Hundsberger, Thomas</creator><creator>Dietmann, Anelia</creator><creator>Jung, Hans H.</creator><creator>Kuntzer, Thierry</creator><creator>Wilder‐Smith, Einar</creator><creator>Martinetti‐Lucchini, Gladys</creator><creator>Petrini, Orlando</creator><creator>Fontana, Stefano</creator><creator>Gowland, Peter</creator><creator>Niederhauser, Christoph</creator><creator>Gobbi, Claudio</creator><creator>Ripellino, Paolo</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6190-1633</orcidid><orcidid>https://orcid.org/0000-0002-8662-9656</orcidid><orcidid>https://orcid.org/0000-0001-7572-8811</orcidid><orcidid>https://orcid.org/0000-0001-6420-8124</orcidid><orcidid>https://orcid.org/0000-0002-7554-0664</orcidid><orcidid>https://orcid.org/0000-0002-8949-0645</orcidid></search><sort><creationdate>202412</creationdate><title>Immune triggers preceding neuralgic amyotrophy</title><author>Sparasci, Davide ; Schilg‐Hafer, Lenka ; Schreiner, Bettina ; Scheidegger, Olivier ; Peyer, Anne‐Kathrin ; Lascano, Agustina Maria ; Vicino, Alex ; Décard, Bernhard Friedrich ; Tsouni, Pinelopi ; Humm, Andrea Monika ; Pianezzi, Enea ; Zezza, Giulia ; Hundsberger, Thomas ; Dietmann, Anelia ; Jung, Hans H. ; Kuntzer, Thierry ; Wilder‐Smith, Einar ; Martinetti‐Lucchini, Gladys ; Petrini, Orlando ; Fontana, Stefano ; Gowland, Peter ; Niederhauser, Christoph ; Gobbi, Claudio ; Ripellino, Paolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2992-a1926d06f3719a27f2256d23f17141fd66390d2758591d89634bd8104392aa113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological properties</topic><topic>Biological samples</topic><topic>Brachial Plexus Neuritis - etiology</topic><topic>Case-Control Studies</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Cytomegalovirus</topic><topic>Disease control</topic><topic>Epstein-Barr virus</topic><topic>Female</topic><topic>Hepatitis</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>immune trigger</topic><topic>Immunization</topic><topic>Immunology</topic><topic>infection</topic><topic>Infections</topic><topic>Male</topic><topic>Middle Aged</topic><topic>neuralgic amyotrophy</topic><topic>Neuromuscular system</topic><topic>Neuropathies</topic><topic>Original</topic><topic>Parsonage–Turner syndrome</topic><topic>Parvoviruses</topic><topic>Prospective Studies</topic><topic>Respiratory diseases</topic><topic>Serological tests</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccination</topic><topic>Varicella</topic><topic>Viral diseases</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sparasci, Davide</creatorcontrib><creatorcontrib>Schilg‐Hafer, Lenka</creatorcontrib><creatorcontrib>Schreiner, Bettina</creatorcontrib><creatorcontrib>Scheidegger, Olivier</creatorcontrib><creatorcontrib>Peyer, Anne‐Kathrin</creatorcontrib><creatorcontrib>Lascano, Agustina Maria</creatorcontrib><creatorcontrib>Vicino, Alex</creatorcontrib><creatorcontrib>Décard, Bernhard Friedrich</creatorcontrib><creatorcontrib>Tsouni, Pinelopi</creatorcontrib><creatorcontrib>Humm, Andrea Monika</creatorcontrib><creatorcontrib>Pianezzi, Enea</creatorcontrib><creatorcontrib>Zezza, Giulia</creatorcontrib><creatorcontrib>Hundsberger, Thomas</creatorcontrib><creatorcontrib>Dietmann, Anelia</creatorcontrib><creatorcontrib>Jung, Hans H.</creatorcontrib><creatorcontrib>Kuntzer, Thierry</creatorcontrib><creatorcontrib>Wilder‐Smith, Einar</creatorcontrib><creatorcontrib>Martinetti‐Lucchini, Gladys</creatorcontrib><creatorcontrib>Petrini, Orlando</creatorcontrib><creatorcontrib>Fontana, Stefano</creatorcontrib><creatorcontrib>Gowland, Peter</creatorcontrib><creatorcontrib>Niederhauser, Christoph</creatorcontrib><creatorcontrib>Gobbi, Claudio</creatorcontrib><creatorcontrib>Ripellino, Paolo</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sparasci, Davide</au><au>Schilg‐Hafer, Lenka</au><au>Schreiner, Bettina</au><au>Scheidegger, Olivier</au><au>Peyer, Anne‐Kathrin</au><au>Lascano, Agustina Maria</au><au>Vicino, Alex</au><au>Décard, Bernhard Friedrich</au><au>Tsouni, Pinelopi</au><au>Humm, Andrea Monika</au><au>Pianezzi, Enea</au><au>Zezza, Giulia</au><au>Hundsberger, Thomas</au><au>Dietmann, Anelia</au><au>Jung, Hans H.</au><au>Kuntzer, Thierry</au><au>Wilder‐Smith, Einar</au><au>Martinetti‐Lucchini, Gladys</au><au>Petrini, Orlando</au><au>Fontana, Stefano</au><au>Gowland, Peter</au><au>Niederhauser, Christoph</au><au>Gobbi, Claudio</au><au>Ripellino, Paolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune triggers preceding neuralgic amyotrophy</atitle><jtitle>European journal of neurology</jtitle><addtitle>Eur J Neurol</addtitle><date>2024-12</date><risdate>2024</risdate><volume>31</volume><issue>12</issue><spage>e16462</spage><epage>n/a</epage><pages>e16462-n/a</pages><issn>1351-5101</issn><issn>1468-1331</issn><eissn>1468-1331</eissn><abstract>Background and purpose
Infections and vaccinations have been identified as potential immunological triggers of neuralgic amyotrophy (NA), but the exact type and frequency of the preceding agents is unknown.
Methods
This was a multicentre, prospective, observational, matched case–control study. NA was diagnosed by neuromuscular experts according to validated clinical criteria and electrodiagnostic studies. Clinical data and biological samples of NA patients were collected within 90 days from disease onset between June 2018 and December 2023. All NA patients were asked about prior infection and vaccination in the month before disease onset. Serological tests for hepatitis E virus, human immunodeficiency virus, severe acute respiratory syndrome coronavirus 2, Epstein–Barr virus, cytomegalovirus, parvovirus B19, varicella‐zoster virus, Borrelia burgdorferi, Mycoplasma pneumoniae and Bartonella henselae were performed in a central laboratory. Each case was matched with a healthy control for age, sex, place of residence and time of blood collection.
Results
Fifty‐seven patients and corresponding controls were included. The mean age was 45 years for both groups. NA onset was preceded by a symptomatic infectious trigger confirmed by microbiological tests in 15/57 (26.3%) patients. Coronavirus disease 2019 vaccination was considered a potential trigger in 7/57 (12.3%) subjects. An acute viral infection was associated with a bilateral involvement of the brachial plexus (p = 0.003, Cramèr's V = 0.43).
Conclusions
Confirmed immune triggers (infection or vaccination) preceded disease onset in 22/57 (38.6%) NA cases. We suggest to test NA patients in the acute phase for intracellular antigens, especially in the case of concomitant bilateral involvement and hepatitis.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>39364568</pmid><doi>10.1111/ene.16462</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6190-1633</orcidid><orcidid>https://orcid.org/0000-0002-8662-9656</orcidid><orcidid>https://orcid.org/0000-0001-7572-8811</orcidid><orcidid>https://orcid.org/0000-0001-6420-8124</orcidid><orcidid>https://orcid.org/0000-0002-7554-0664</orcidid><orcidid>https://orcid.org/0000-0002-8949-0645</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1351-5101 |
ispartof | European journal of neurology, 2024-12, Vol.31 (12), p.e16462-n/a |
issn | 1351-5101 1468-1331 1468-1331 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11554871 |
source | MEDLINE; Wiley Online Library Open Access; Wiley Online Library Journals Frontfile Complete; PubMed Central |
subjects | Adult Aged Biological properties Biological samples Brachial Plexus Neuritis - etiology Case-Control Studies Coronaviruses COVID-19 COVID-19 - complications COVID-19 - immunology COVID-19 Vaccines - immunology Cytomegalovirus Disease control Epstein-Barr virus Female Hepatitis HIV Human immunodeficiency virus Humans immune trigger Immunization Immunology infection Infections Male Middle Aged neuralgic amyotrophy Neuromuscular system Neuropathies Original Parsonage–Turner syndrome Parvoviruses Prospective Studies Respiratory diseases Serological tests Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Vaccination Varicella Viral diseases Viral infections |
title | Immune triggers preceding neuralgic amyotrophy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T17%3A55%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20triggers%20preceding%20neuralgic%20amyotrophy&rft.jtitle=European%20journal%20of%20neurology&rft.au=Sparasci,%20Davide&rft.date=2024-12&rft.volume=31&rft.issue=12&rft.spage=e16462&rft.epage=n/a&rft.pages=e16462-n/a&rft.issn=1351-5101&rft.eissn=1468-1331&rft_id=info:doi/10.1111/ene.16462&rft_dat=%3Cproquest_pubme%3E3112861386%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3126823128&rft_id=info:pmid/39364568&rfr_iscdi=true |